DSGN

Design Therapeutics, Inc. is a biotechnology company developing therapies for degenerative diseases caused by nucleotide repeat expansions. The company's GeneTAC (Gene Targeted Chimera) platform aims to eliminate toxic repeat expansion proteins that cause conditions such as Friedreich's ataxia, myotonic dystrophy type-1, and Fuchs endothelial corneal dystrophy. Design Therapeutics' approach uses small molecules designed to target and degrade the aberrant proteins produced by these genetic mutations. The company is advancing multiple programs through clinical development. Design Therapeutics focuses on diseases with significant unmet medical needs where current treatment options are limited.